Benitec Biopharma (BNTC) Return on Capital Employed (2020 - 2025)
Benitec Biopharma (BNTC) reported Return on Capital Employed of 34.4% for Q4 2025, up 271.0% on a YoY basis from 9.27% in Q4 2024, and up 28.02% sequentially from 47.79% in Q3 2025.
Benitec Biopharma (BNTC) Return on Capital Employed (2020 - 2025) Analysis & Trends
Benitec Biopharma (BNTC) has 6 years of Return on Capital Employed data on file, last reported at 34.4% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 271.0% year-over-year to 34.4%; the trailing twelve-month figure through Dec 2025 stood at 34.4% (up 271.0% YoY), and the FY2025 full-year result was 56.36%, up 3969.0% from the prior year.
- Return on Capital Employed advanced to 34.4% in Q4 2025, from 47.79% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 34.4% in Q4 2025 to a low of 807.15% in Q2 2023.
- A 5-year average of 167.19% and a median of 123.12% in 2021 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 48171 bps in 2023 and surged 72873 bps in 2024, its largest moves.
- Tracing BNTC's Return on Capital Employed over 5 years: stood at 128.71% in 2021, then slipped by 14 bps to 146.86% in 2022, then advanced by 20 bps to 117.53% in 2023, then jumped by 68 bps to 37.11% in 2024, then grew by 7 bps to 34.4% in 2025.
- Business Quant data shows BNTC's Return on Capital Employed at 34.4% in Q4 2025, 47.79% in Q3 2025, and 37.11% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Benitec Biopharma | 46.45 Mn | 46.45 Mn | - | -34.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.40% |
| Sep 30, 2025 | -47.79% |
| Dec 31, 2024 | -37.11% |
| Sep 30, 2024 | -40.06% |
| Jun 30, 2024 | -78.42% |
| Mar 31, 2024 | -145.82% |
| Dec 31, 2023 | -117.53% |
| Sep 30, 2023 | -181.52% |
| Jun 30, 2023 | -807.15% |
| Mar 31, 2023 | -278.88% |
| Dec 31, 2022 | -146.86% |
| Sep 30, 2022 | -194.99% |
| Jun 30, 2022 | -325.44% |
| Mar 31, 2022 | -167.54% |
| Dec 31, 2021 | -128.71% |
| Sep 30, 2021 | -87.35% |
| Jun 30, 2021 | -84.80% |
| Mar 31, 2021 | -105.01% |
| Dec 31, 2020 | -95.73% |
| Sep 30, 2020 | -106.14% |